Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

By sjmartinez • January 7, 2025

Blauvelt A, Kircik L, Schlesinger T, Pierce E, Burge R, Behling M, Atwater AR, ElMaraghy H, Armstrong A. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025 Dec;36(1):2442720. doi: 10.1080/09546634.2024.2442720. Epub 2025 Jan 6. PMID: 39761965.

Tags: atopic dermatitis, Dermatology, Eczema Area and Severity Index, lebrikizumab, Publications, Quality of Life

Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison

Armstrong A, Kircik L, Metelitsa A, Warren RB, Rodriguez A, Volc S, Issa N, Chovatiya R, von Eyben R, Festini T, Johansen P, Ehst B.[...]

Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement

Akiska YM, Fu J, Castelo-Soccio L, Mathes E, Mirmirani P, Jamerson T, Sibbald C; and The Pediatric Low-Dose Oral Minoxidil Consensus Expert Group; Spagnol Abraham[...]

Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply

Armstrong AW, Nong Y, Merola JF. Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply. JAMA Dermatol. 2026 Sep 23. doi: 10.1001/jamadermatol.2026.3645. Epub ahead of print.[...]